CHCT Stock Analysis: Community Healthcare Trust | NYSE
REIT - Healthcare Facilities | NYSE, USA | Market Cap: 428m USD | 12M Return: 9.7% | US20369C1062 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 6.03M
Qual. Beats: 0
Rev. Trend: 96.9%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.3 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Community Healthcare Trust Incorporated (NYSE: CHCT) is a real estate investment trust (REIT) based in Franklin, Tennessee, that owns income-producing real estate properties leased to operators of outpatient healthcare services across the United States. Founded on March 28, 2014, the company was established to focus on healthcare-related real estate in targeted sub-markets throughout the country.
As of March 31, 2026, the company reported total investments of approximately $1.2 billion across 198 real estate properties located in 36 states, encompassing roughly 4.5 million square feet of leasable space. CHCT trades as a small-cap stock and is classified within the Health Care REITs sub-industry of the Real Estate sector.
As a REIT, CHCT is generally required to distribute a significant portion of its taxable income to shareholders in the form of dividends, a structure common to publicly traded REITs. Healthcare REITs such as CHCT typically operate on long-term lease agreements with medical providers, generating relatively stable rental income tied to the broader healthcare delivery system.
- Outpatient rental income grows on property acquisitions and escalators
- Higher interest rates pressure AFFO and dividend coverage
- Medicare and Medicaid reimbursement cuts weaken tenant credit quality
| Net Income: 21.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 2.13 > 1.0 |
| NWC/Revenue: 31.90% < 20% (prev -167.2%; Δ 199.1% < -1%) |
| CFO/TA 0.06 > 3% & CFO 59.5m > Net Income 21.0m |
| Net Debt (565.8m) to EBITDA (94.9m): 5.96 < 3 |
| Current Ratio: 402.2 > 1.5 & < 3 |
| Outstanding Shares: last quarter (27.0m) vs 12m ago 0.79% < -2% |
| Gross Margin: 63.21% > 18% (prev 71.14%; Δ -7.93% > 0.5%) |
| Asset Turnover: 12.64% > 50% (prev 12.22%; Δ 0.42% > 0%) |
| Interest Coverage Ratio: 1.68 > 6 (EBIT TTM 51.7m / Interest Expense TTM 30.8m) |
| A: 0.04 (Total Current Assets 39.8m - Total Current Liabilities 99.0k) / Total Assets 1.00b |
| B: -0.32 (Retained Earnings -317.5m / Total Assets 1.00b) |
| C: 0.05 (EBIT TTM 51.7m / Avg Total Assets 984.9m) |
| D: 0.70 (Book Value of Equity 414.2m / Total Liabilities 589.4m) |
| Altman-Z'' = 0.32 = B |
| DSRI: 0.98 (Receivables 37.1m/36.0m, Revenue 124.5m/118.1m) |
| GMI: 1.13 (GM 71.14% / 63.21%) |
| AQI: 1.01 (AQ_t 0.96 / AQ_t-1 0.95) |
| SGI: 1.05 (Revenue 124.5m / 118.1m) |
| TATA: -0.04 (NI 21.0m - CFO 59.5m) / TA 1.00b) |
| Beneish M = -2.89 (Cap -4..+1) = A |
As of September 02, 2026, the stock is trading at USD 14.89 with a total of 321,635 shares traded. Over the past week, the price has changed by -0.87%, over one month by -16.59%, over three months by -11.71% and over the past year by +9.72%.
Current recommended Stop Loss: 14.30 (which is 4% or 1.4 ATR below the current price).
Community Healthcare Trust has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy CHCT.
- StrongBuy: 2
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 18.3 | 22.6% |
P/E Trailing = 22.2985
P/E Forward = 37.3134
P/S = 3.4307
P/B = 1.039
Revenue TTM = 124.5m USD
EBIT TTM = 51.7m USD
EBITDA TTM = 94.9m USD
Long Term Debt = 274.3m USD (from longTermDebt, last quarter)
Short Term Debt = 99.0k USD (from shortTermDebt, last quarter)
Debt = 568.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 3.98m
Net Debt = 565.8m USD (calculated: Debt 568.5m - CCE 2.67m)
Enterprise Value = 993.9m USD (428.1m + Debt 568.5m - CCE 2.67m)
Interest Coverage Ratio = 1.68 (Ebit TTM 51.7m / Interest Expense TTM 30.8m)
EV/FCF = 16.77x (Enterprise Value 993.9m / FCF TTM 59.3m)
FCF Yield = 5.96% (FCF TTM 59.3m / Enterprise Value 993.9m)
FCF Margin = 47.59% (FCF TTM 59.3m / Revenue TTM 124.5m)
Net Margin = 16.85% (Net Income TTM 21.0m / Revenue TTM 124.5m)
Gross Margin = 63.21% ((Revenue TTM 124.5m - Cost of Revenue TTM 45.8m) / Revenue TTM)
Gross Margin QoQ = 81.22% (prev 79.80%)
Tobins Q-Ratio = 0.99 (Enterprise Value 993.9m / Total Assets 1.00b)
Interest Expense / Debt = 5.41% (Interest Expense 30.8m / Debt 568.5m)
Taxrate = 0.45% (23.0k / 5.12m)
NOPAT = 51.5m (EBIT 51.7m * (1 - 0.45%))
Current Ratio = 402.2 (out of range, set to none) (Total Current Assets 39.8m / Total Current Liabilities 99.0k)
Debt / Equity = 1.37 (Debt 568.5m / totalStockholderEquity, last quarter 414.2m)
Debt / EBITDA = 5.96 (Net Debt 565.8m / EBITDA 94.9m)
Debt / FCF = 9.55 (Net Debt 565.8m / FCF TTM 59.3m)
Total Stockholder Equity = 422.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 2.13% (Net Income 21.0m / Total Assets 1.00b)
RoE = 4.96% (Net Income TTM 21.0m / Total Stockholder Equity 422.9m)
RoCE = 7.42% (EBIT 51.7m / Capital Employed (Equity 422.9m + L.T.Debt 274.3m))
RoIC = 5.15% (NOPAT 51.5m / Invested Capital 1.00b)
WACC = 5.39% (E(428.1m)/V(996.6m) * Re(5.40%) + D(568.5m)/V(996.6m) * Rd(5.41%) * (1-Tc(0.00)))
Discount Rate = 5.40% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.44 | Cagr: 1.21%
[DCF] Terminal Value 77.97% ; FCFF base≈50.1m ; Y1≈57.5m ; Y5≈84.6m
[DCF] Fair Price = 24.68 (EV 1.27b - Net Debt 565.8m = Equity 707.0m / Shares 28.7m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.27 | # QB: 0
Revenue Correlation: 96.91 | Revenue CAGR: 4.00% | SUE: -0.62 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=0.00 | Chg30d=N/A | Revisions=N/A | GrowthEPS=+0.0% | GrowthRev=+4.9%
EPS next Year (2027-12-31): EPS=0.00 | Chg30d=N/A | Revisions=N/A | GrowthEPS=+0.0% | GrowthRev=+6.3%